A Study of ARRY-142886 in Patients With Advanced Cancer

NCT00085787 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: ARRY-142886, MEK inhibitor; oral

Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer